{"id":"W3005336040","doi":"10.1200/jco.19.02044","title":"EV-101: A Phase I Study of Single-Agent Enfortumab Vedotin in Patients With Nectin-4–Positive Solid Tumors, Including Metastatic Urothelial Carcinoma","year":2020,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Wnt/β-catenin signaling in development and cancer","field":"Biochemistry, Genetics and Molecular Biology","cited_by":327,"is_retracted":false,"has_abstract":true,"ca_institutions":"Alberta Cancer Foundation; Princess Margaret Cancer Centre; University Health Network","funders":"National Center for Advancing Translational Sciences; National Cancer Institute; Jounce Therapeutics; AstraZeneca; Bristol-Myers Squibb; Mirati Therapeutics; Syndax Pharmaceuticals; Clovis Oncology; Constellation Pharmaceuticals; Astellas Pharma; Genentech; INOVIO Pharmaceuticals","keywords":"Medicine; Tolerability; Internal medicine; Adverse effect; Rash; Nausea; Oncology; Regimen; Response Evaluation Criteria in Solid Tumors; Chemotherapy; Phases of clinical research; Gastroenterology","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001110355,0.0001813093,0.0009962734,0.00007765389,0.0000374646,0.000009347382,0.0002708215,0.0001313652,0.00003411272],"category_scores_gemma":[0.001052309,0.0001374843,0.0001760388,0.000163032,0.0001076095,0.00001247329,0.0001114131,0.0004026854,0.000001642026],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.00006957605,"about_ca_system_score_gemma":0.001059895,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0000193235,"about_ca_topic_score_gemma":0.00002677315,"domain_scores_codex":[0.9967217,0.000464048,0.00195873,0.0002743885,0.0003501228,0.0002309684],"domain_scores_gemma":[0.9973773,0.0002223753,0.001669586,0.0001189754,0.0004049466,0.0002067984],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"observational","study_design_scores_codex":[0.03927505,0.01694207,0.8749006,0.00006258363,0.001358235,0.0005287572,0.003784819,0.0009732123,0.03784454,0.000005744954,0.0009957701,0.02332863],"study_design_scores_gemma":[0.1080977,0.2988884,0.5096524,0.0002520572,0.0008178118,0.00005496952,0.004233746,0.0001988751,0.0740802,0.00004892598,0.002907934,0.0007670082],"study_design_candidate":"observational","study_design_consensus":"observational","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9985428,0.00009613892,0.0002902769,0.0002471877,0.0003064029,0.000345789,0.000008062729,0.000002446859,0.0001608278],"genre_scores_gemma":[0.9981281,0.00001349583,0.0008509607,0.000583944,0.0003694145,0.000007174522,0.00001144602,0.00002177903,0.0000137052],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.3652482,"threshold_uncertainty_score":0.5606446,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.1093500930747905,"score_gpt":0.4089754387298743,"score_spread":0.2996253456550838,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}